[go: up one dir, main page]

MX2009009952A - Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida. - Google Patents

Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.

Info

Publication number
MX2009009952A
MX2009009952A MX2009009952A MX2009009952A MX2009009952A MX 2009009952 A MX2009009952 A MX 2009009952A MX 2009009952 A MX2009009952 A MX 2009009952A MX 2009009952 A MX2009009952 A MX 2009009952A MX 2009009952 A MX2009009952 A MX 2009009952A
Authority
MX
Mexico
Prior art keywords
diphenylhexanamide
hydrochloride salt
tivdroxyphenoxy
azetidiï
ethyl
Prior art date
Application number
MX2009009952A
Other languages
English (en)
Inventor
Kim James
Paul Alan Glossop
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MX2009009952A publication Critical patent/MX2009009952A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a la sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamid a o forma derivada de la misma y a su uso como un medicamento.
MX2009009952A 2007-03-16 2008-03-06 Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida. MX2009009952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89516307P 2007-03-16 2007-03-16
PCT/IB2008/000622 WO2008135819A1 (en) 2007-03-16 2008-03-06 Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide

Publications (1)

Publication Number Publication Date
MX2009009952A true MX2009009952A (es) 2009-10-08

Family

ID=39591485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009952A MX2009009952A (es) 2007-03-16 2008-03-06 Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.

Country Status (23)

Country Link
US (1) US8263583B2 (es)
EP (1) EP2125714B1 (es)
JP (1) JP4277051B2 (es)
KR (1) KR101120227B1 (es)
CN (2) CN101641327A (es)
AR (1) AR065714A1 (es)
AT (1) ATE512132T1 (es)
AU (1) AU2008247095B2 (es)
BR (1) BRPI0808413A2 (es)
CA (1) CA2678683C (es)
CY (1) CY1111701T1 (es)
DK (1) DK2125714T3 (es)
ES (1) ES2364727T3 (es)
IL (1) IL200403A (es)
MX (1) MX2009009952A (es)
NZ (1) NZ579056A (es)
PL (1) PL2125714T3 (es)
PT (1) PT2125714E (es)
RU (1) RU2422439C2 (es)
SI (1) SI2125714T1 (es)
TW (1) TWI348907B (es)
WO (1) WO2008135819A1 (es)
ZA (1) ZA200906462B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20200031769A1 (en) 2017-03-15 2020-01-30 Mylan Laboratories Limited Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3990091A4 (en) * 2019-06-25 2023-07-12 Mylan Laboratories Ltd. METHODS AND INTERMEDIATES FOR THE PREPARATION OF 5-[3-(3-HYDROXYPHENOXY)AZETIDINE-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE HYDROCHLORIDE SALT
US20230293430A1 (en) * 2020-06-26 2023-09-21 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
CN113577059B (zh) * 2021-08-02 2022-05-20 山东大学齐鲁医院(青岛) 一种用于小儿哮喘的活性药物
WO2025095813A1 (ru) * 2023-11-03 2025-05-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые соединения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001118A3 (en) * 1996-12-02 2001-06-28 Kyorin Seiyaku Kk N-substituted pyrrolidine derivatives, process for preparing the same and pharmaceutical compositions containing them
JPH11100366A (ja) 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1928821B1 (en) * 2005-09-21 2009-01-07 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
JP2010504316A (ja) * 2006-09-22 2010-02-12 ファイザー・リミテッド ムスカリン様受容体アンタゴニストとしてのアゼチジン誘導体

Also Published As

Publication number Publication date
EP2125714B1 (en) 2011-06-08
CA2678683A1 (en) 2008-11-13
US8263583B2 (en) 2012-09-11
ATE512132T1 (de) 2011-06-15
TW200904408A (en) 2009-02-01
EP2125714A1 (en) 2009-12-02
DK2125714T3 (da) 2011-07-25
PT2125714E (pt) 2011-07-14
ZA200906462B (en) 2010-06-30
WO2008135819A8 (en) 2009-08-27
KR20090110944A (ko) 2009-10-23
CN103351367B (zh) 2015-06-10
PL2125714T3 (pl) 2011-10-31
JP4277051B2 (ja) 2009-06-10
CY1111701T1 (el) 2015-10-07
KR101120227B1 (ko) 2012-03-20
AR065714A1 (es) 2009-06-24
JP2009001543A (ja) 2009-01-08
TWI348907B (en) 2011-09-21
RU2422439C2 (ru) 2011-06-27
US20100113409A1 (en) 2010-05-06
BRPI0808413A2 (pt) 2014-07-15
AU2008247095B2 (en) 2012-12-13
WO2008135819A1 (en) 2008-11-13
CN101641327A (zh) 2010-02-03
ES2364727T3 (es) 2011-09-13
CA2678683C (en) 2012-05-15
IL200403A (en) 2014-08-31
CN103351367A (zh) 2013-10-16
SI2125714T1 (sl) 2011-10-28
RU2009134512A (ru) 2011-03-20
HK1189591A1 (en) 2014-06-13
NZ579056A (en) 2011-07-29
IL200403A0 (en) 2010-04-29
AU2008247095A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
IN2012DN01233A (es)
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
MX343625B (es) Composiciones plagicidas.
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2009010071A (es) Derivados de aril isoxazolina insecticidas.
WO2009077500A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
MY153985A (en) Aminotriazole derivatives as alx agonists
WO2009077497A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2008070268A3 (en) Pharmaceutical compositions
TW200942524A (en) Novel aminomethyl benzene derivatives
EA201070689A1 (ru) Композиция для личного ухода
TW200738651A (en) Cyclohexyl sulfonamide derivatives
TW200942530A (en) Pyridine compounds
MX2011012533A (es) Espiro-epoxidos como productos intermedios.
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
MX2010002007A (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
JO2773B1 (en) 2-oxo-alkyl-1-piprazine-2-1 derivatives, their preparation and therapeutic use.
MX2007010143A (es) Formas cristalinas de intermedio de linezolid.
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration